Holen Sie sich die Stockscreener-App
88.27
2.76%
-2.52
Schlusskurs vom Vortag:
$90.79
Offen:
$88.07
24-Stunden-Volumen:
153.74K
Relative Volume:
0.12
Marktkapitalisierung:
$7.79B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-37.44
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
+1.41%
1M Leistung:
-15.85%
6M Leistung:
+114.95%
1J Leistung:
+427.36%
1-Tages-Spanne:
$87.83
$89.57
1-Wochen-Bereich:
$84.68
$92.10
52-Wochen-Spanne:
$14.51
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
88.30 | 8.01B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com India
SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada
Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com
An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan
Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares - Investing.com
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares By Investing.com - Investing.com India
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Canada
Spyre Therapeutics (SYRE) CFO sells over 25K shares in planned trades - Stock Titan
Spyre Therapeutics (SYRE) CEO sells shares in preset plan - Stock Titan
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Three September conferences will include Spyre Therapeutics. Webcasts will be available. - Stock Titan
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Multimillion-dollar stock sale planned by Spyre Therapeutics (SYRE) officer—see how many shares are on the block - Stock Titan
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked - Yahoo Finance
Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles - sahmcapital.com
Spyre reveals mid-stage miss for TL1A antibody in rheumatoid arthritis - The Pharma Letter
Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade) - Seeking Alpha
Stifel reiterates Spyre stock Buy rating after RA study results By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127 - Moomoo
Stifel reiterates Spyre stock Buy rating after RA study results - Investing.com
Deutsche Bank Adjusts Spyre Therapeutics PT to $127 From $135, Maintains Buy Rating - marketscreener.com
Why is Spyre Therapeutics stock sliding today? By Investing.com - Investing.com Canada
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis - Yahoo Finance
Spyre reports mixed phase 2 results for SPY072 in arthritis By Investing.com - Investing.com Nigeria
Stocks to Watch : Intuit, Spyre Therapeutics, Zoom Communications, nCino - marketscreener.com
Spyre Therapeutics stock tumbles on trial results By Investing.com - Investing.com Australia
Spyre reports mixed phase 2 results for SPY072 in arthritis - Investing.com
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 - The Manila Times
Spyre Therapeutics reports statistically significant Phase 2 RA signals for SPY072 but will not prioritize monotherapy - TradingView
Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, NCino - Moomoo
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk? - Yahoo Finance
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
SYRE|Spyre Therapeutics Inc|Price:106.250|Chg%:-0.240 - tradingkey.com
RTW Investments, LP Expands Spyre Therapeutics (SYRE) Stake With Strategic Add - GuruFocus
Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch? - simplywall.st
This Stock’s Already Up Nearly 600% Over the Past Year - Yahoo Finance
Price to book forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighHere's What Happened - MarketBeat
Spyre Therapeutics stock hits 52-week high at 108.16 USD - Investing.com
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):